NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
- Active, not recruiting
- Dec 4, 2020
- 1 min read
Updated: Feb 10, 2024
NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
Sponsor
Jacob Laubach
Collaborator
Sanofi
ClinicalTrials.gov Identifier: NCT04653246
Official Title: Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
First Posted : December 4, 2020
Click here to see details on ClinicalTrials.gov
Drug: Isatuximab
Drug: Lenalidomide
Drug: Bortezomib Injection
Drug: Dexamethasone
Location
United States, Massachusetts
